Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michal Becker-Cohen

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
Journal of Parkinson'S Disease|February 22, 2021
Parkinson's Clustering in Families of Non-Neuronopathic N370S GBA Mutation Carriers Indicates the Presence of Genetic ModifiersTama Dinur, Michal Becker-Cohen, Shoshana Revel-Vilk, et al.
Journal of Clinical Medicine|November 11, 2022
Real-Life Experience with Oral Eliglustat in Patients with Gaucher Disease Previously Treated with Enzyme Replacement TherapyMajdolen Istaiti, Michal Becker-Cohen, Tama Dinur, et al.
Molecular Neurobiology|March 30, 2016
The Interaction of UDP-N-Acetylglucosamine 2-Epimerase/N-Acetylmannosamine Kinase (GNE) and Alpha-Actinin 2 Is Altered in GNE Myopathy M743T MutantAvi Harazi, Michal Becker-Cohen, Hagit Zer, et al.
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|April 30, 2020
Response of ophthalmologists in Israel to the novel coronavirus (2019-nCoV) outbreakLauren M Wasser, Elishai Assayag, Maria Tsessler, et al.
Journal of Clinical Medicine|March 29, 2023
The Bone Biomarker of Quantitative Chemical Shift Imaging in Patients with Type 1 Gaucher Disease Receiving Low-Dose Long-Term Enzyme Replacement TherapyAri Zimran, Jeff Szer, Michal Becker-Cohen, et al.
Journal of Neuromuscular Diseases|November 22, 2021
Pre Clinical Assessment of AAVrh74.MCK.GNE Viral Vector Therapeutic Potential: Robust Activity Despite Lack of Consistent Animal Model for GNE MyopathyStella Mitrani-Rosenbaum, Lena Yakovlev, Michal Becker Cohen, et al.
Neuromuscular Disorders : NMD|August 2, 2020
The glycomic sialylation profile of GNE Myopathy muscle cells does not point to consistent hyposialylation of individual glycoconjugatesIlan Sela, Victoria Goss, Michal Becker-Cohen, et al.
Orphanet Journal of Rare Diseases|October 14, 2020
Patient reported outcome measures in a large cohort of patients with type 1 Gaucher diseaseTama Dinur, Majdolen Istaiti, Dafna Frydman, et al.
Plos One|July 7, 2011
GNE is involved in the early development of skeletal and cardiac muscleIrit Milman Krentsis, Ilan Sela, Rachel Eiges, et al.
International Journal of Molecular Sciences|July 24, 2021
Impact of Long-Term Enzyme Replacement Therapy on Glucosylsphingosine (Lyso-Gb1) Values in Patients with Type 1 Gaucher Disease: Statistical Models for Comparing Three Enzymatic FormulationsTama Dinur, Ulrike Grittner, Shoshana Revel-Vilk, et al.
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
Journal of Parkinson'S Disease|February 22, 2021
Parkinson's Clustering in Families of Non-Neuronopathic N370S GBA Mutation Carriers Indicates the Presence of Genetic ModifiersTama Dinur, Michal Becker-Cohen, Shoshana Revel-Vilk, et al.
Journal of Clinical Medicine|November 11, 2022
Real-Life Experience with Oral Eliglustat in Patients with Gaucher Disease Previously Treated with Enzyme Replacement TherapyMajdolen Istaiti, Michal Becker-Cohen, Tama Dinur, et al.
Molecular Neurobiology|March 30, 2016
The Interaction of UDP-N-Acetylglucosamine 2-Epimerase/N-Acetylmannosamine Kinase (GNE) and Alpha-Actinin 2 Is Altered in GNE Myopathy M743T MutantAvi Harazi, Michal Becker-Cohen, Hagit Zer, et al.
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|April 30, 2020
Response of ophthalmologists in Israel to the novel coronavirus (2019-nCoV) outbreakLauren M Wasser, Elishai Assayag, Maria Tsessler, et al.
Journal of Clinical Medicine|March 29, 2023
The Bone Biomarker of Quantitative Chemical Shift Imaging in Patients with Type 1 Gaucher Disease Receiving Low-Dose Long-Term Enzyme Replacement TherapyAri Zimran, Jeff Szer, Michal Becker-Cohen, et al.
Journal of Neuromuscular Diseases|November 22, 2021
Pre Clinical Assessment of AAVrh74.MCK.GNE Viral Vector Therapeutic Potential: Robust Activity Despite Lack of Consistent Animal Model for GNE MyopathyStella Mitrani-Rosenbaum, Lena Yakovlev, Michal Becker Cohen, et al.
Neuromuscular Disorders : NMD|August 2, 2020
The glycomic sialylation profile of GNE Myopathy muscle cells does not point to consistent hyposialylation of individual glycoconjugatesIlan Sela, Victoria Goss, Michal Becker-Cohen, et al.
Orphanet Journal of Rare Diseases|October 14, 2020
Patient reported outcome measures in a large cohort of patients with type 1 Gaucher diseaseTama Dinur, Majdolen Istaiti, Dafna Frydman, et al.
Plos One|July 7, 2011
GNE is involved in the early development of skeletal and cardiac muscleIrit Milman Krentsis, Ilan Sela, Rachel Eiges, et al.
International Journal of Molecular Sciences|July 24, 2021
Impact of Long-Term Enzyme Replacement Therapy on Glucosylsphingosine (Lyso-Gb1) Values in Patients with Type 1 Gaucher Disease: Statistical Models for Comparing Three Enzymatic FormulationsTama Dinur, Ulrike Grittner, Shoshana Revel-Vilk, et al.
Pageof 4